UPDATE: Oppenheimer Upgrades DexCom (DXCM) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Canaccord Genuity Reiterates Buy on DexCom (DXCM) Following FDA Approval of DexCom's G5 Mobile
December 21, 2016 10:17 AM ESTCanaccord Genuity reiterated a Buy rating and $70.00 price target on DexCom (NASDAQ: DXCM) following the company's announced FDA approval of DexCom's G5 mobile for "non-adjunctive use". Notably, the FDA stated that although G5 "still requires two finger-stick calibrations, it eliminates the need for any additional finger-stick blood... More
